Individual Risk Assessment for COVID-19 for At-Risk Employees

Completing the risk assessment:

This should be completed for all vulnerable staff

- This can be undertaken by line manager or supervisor
- 2. Involve the member of staff
- 3. Consider actions to minimise risk
- 4. Agree on risk management with the staff member
- 5. Discuss the work options with the employee and use the checklist to indicate which measures will be implemented.

The manager and staff member should consider together, in the light of the risk assessment, whether alternative work arrangements are appropriate and practicable.

Key considerations:

- Limit/avoid duration of close interaction with individuals. Virtual meetings/telephonic conversations are advised.
- 2. Maintain ALL social distancing rules should you meet face to face.
- Consider whether public transport /rush hour can be avoided through adjustments to work hours
- 4. Arrange to travel using private transport/lift clubs
- 5. Use PPE appropriately
- Consider remote working if the staff member is enabled including access to equipment and internet

Classify the employee vulnerability

VERY HIGH VULNERABILITY:

- Solid organ transplant recipients
- People with specific cancers or receiving immunosuppressive treatment for their cancer:
 - o undergoing active chemotherapy or radical radiotherapy for lung cancer
 - cancers of the blood or bone marrow such as leukemia, lymphoma or myeloma who are at any stage of treatment
 - o receiving immunotherapy or other continuing antibody treatments for cancer
 - o receiving targeted cancer treatments which can affect the immune system, such as protein kinase inhibitors or Poly ADP-ribose Polymerase (PARP) inhibitors
- People who have had bone marrow or stem cell transplants in the last 6 months, or who are still taking immunosuppressive drugs.
- People with severe respiratory conditions including cystic fibrosis, severe and unstable asthma and severe Chronic Obstructive Pulmonary Disease (COPD), or current active tuberculosis of the lung.
- People with rare diseases and inborn errors of metabolism that significantly increase the risk of infections (such as Severe Combined Immunodeficiency (SCID), homozygous sickle cell).
- People on immunosuppressive therapies sufficient to significantly increase risk of infection.
- Women who are pregnant with significant heart disease, congenital or acquired.

HIGH VULNERABILITY:

- Age >60 with one or more diseases/conditions as listed.
- Chronic lung problems (moderate to severe asthma, previous complicated TB, etc.). Pulmonary
 Tuberculosis untreated or in early treatment and who have not completed the intensive phase or
 first two months of treatment in line with the National Department of Health Standard Treatment
 Guidelines. Asthma which requires treatment with high dose inhaled corticosteroids plus a second
 controller (and/or systemic corticosteroids) to prevent it from becoming 'uncontrolled' or which
 remains 'uncontrolled' despite this therapy.
- Confirmed clinical diagnosis of congestive cardiac failure or other serious cardiovascular disease

- Severe hypertension: systolic BP ≥180 mmHg and/or diastolic BP ≥110 mmHg.
- Confirmed cerebrovascular disease, including stroke, and transient ischemic attack
- Those who are moderately or intermittently immunocompromised
- Severe obesity (BMI >40)
- Underlying medical conditions, particularly if not well controlled, such as type II Diabetes Mellitus (HBA1c ≥7.5% within last 6 months); Chronic Kidney Disease with an eGFR < 45; or liver disease
- More than 28 weeks pregnant

MEDIUM VULNERABILITY:

- Less than 28 weeks pregnant, but otherwise healthy
- Age between 40 and 60, with controlled medical conditions (hypertension, diabetes, cardiovascular disease, etc.)
- Moderate hypertension: systolic BP 160-179mmHg and/or diastolic BP 100-109 mmHg.
- Previous lung TB, but recovered without complications

LOW VULNERABILITY:

- Physiologically young
- Healthy

Individual Risk Assessment

Name of Staff Member				
PERSAL number				
Rank				
School/Directorate				
Name of Supervisor				
Date				
Employee Comorbidity – (Evidence)				
Employee vulnerability group	Low	Medium	High	Very high
Validity of Medical Certificate			treatment noted	Recommendation of Medical Practitioner stated
Yes/No				

Agreed action plan to manage the employee Indicate those that have been agreed to		
Dedicated alcohol-based hand rub provided for the employee		
Protective isolation and physical distancing (e.g. providing a dedicated, clean office, etc.)		
Adaptation of duties		
Limit duration of close interaction learners/colleagues and/or the public		
Alternative accommodation in a lower exposure-risk area-cellular office/boardroom/floor/classroom		
Providing alternative transport arrangements to prevent public transport exposures		
Implementing a co-worker screening programme		
Sharing of relevant COVID related information and social distancing information		
Specialized personal protective equipment (PPE) provided		
Working off-site (remotely); the necessary equipment, internet access, etc. is available		
Special Leave (Risk to COVID-19)		
Other, please specify:		

Employee Agree/Not Agree	Written evidence to be provided (Email/IM/Signature)

Recommendation by Principal/Manager (M	ark with X)	
Recommended	Not Recommended	
	Recommended	
REMARKS:		
		MANAGER'S/SUPERVISOR'S SIGNATURE
DATE		

INDIVIDUAL RISK ASSESSMENT CHECKLIST FOR COVID-19 FOR AT-RISK EMPLOYEES

REQUIREMENTS	YES/NO (V/X)
At-Risk Declaration (Employee)	
Assessment (Principal/Manager)	
Individual Risk Assessment Completed by	
Manager/Principal	
Medical Evidence	
Certificate from Medical Practitioner available	
Signature (Manager/Principal)	
Employee Signature/Evidence	

Approved by Circuit Manager/Middle Manager/Senior Manager (Mark with X)					
Approved	Not Approved				
REMARK:					
		MANAGER'S/SUPERVISOR'S SIGNATURE			
DATE					